Browse our 650+ Publications
Latest Publications
Early peripheral blood and bone marrow MRD as prognostic markers in quadruplet‐treated multiple myeloma without transplant
Derman BA, et al.
Hemasphere
August 2025
Authors and Affiliates
Benjamin A. Derman1 | Jennifer Cooperrider1 | Anna Pula1,2 |
Heidi Simmons3 | Tadeusz Kubicki1,4 | Jeffrey Zonder5 | Aimaz Afrough6 |
David Grinblatt7 | Jacalyn Rosenblatt8 | Larry D. Anderson Jr.6 | Andrew Kin5 |
David Avigan6 | Sunil Narula1 | Shayan Rayani1 | Ken Jiang1 | Ajay Major9 |
Theodore Karrison1 | Allison Jacob3 | Andrzej J. Jakubowiak1
1University of Chicago, Chicago, Illinois, USA
2Department of Hematology, Medical University of Lodz, Łódź, Poland
3Adaptive Biotechnologies, Seattle, Washington, USA
4Poznan University of Medical Sciences, Poznan, Poland
5Karmanos Cancer Institute, Wayne State University, Detroit, Michigan, USA
6Simmons Comprehensive Cancer Center, UT Southwestern Medical Center,
Dallas, Texas, USA
7Endeavor Health, Evanston, Illinois, USA
8Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA
9University of Colorado, Denver, Colorado, USA
Carfilzomib–lenalidomide–dexamethasone versus lenalidomide–dexamethasone in patients with newly diagnosed myeloma ineligible for autologous stem-cell transplantation (EMN20): a randomised, open-label, multicentre, phase 3 trial
Bringhen S, et al.
Lancet Haematology
August 2025
Authors and Affiliates
Sara Bringhen, Lorenzo Cani, Elisabetta Antonioli, Daniele Derudas, Francesca Fazio, Alessandra Larocca, Sonia Ronconi, Claudia Cellini,
Antonietta Pia Falcone, Fabrizio Accardi, Anna Marina Liberati, Piero Galieni, Angelo Belotti, Anna Maria Cafro, Roberto Ria, Giulia Benevolo,
Iolanda Donatella Vincelli, Donato Mannina, Flavia Lotti, Benedetto Bruno, Vincenzo Marasco, Rita Mazza, Patrizia Tosi, Elena Rivolti,
Mario Boccadoro, Mattia D’Agostino
SSD Clinical Trial in
Oncoematologia e Mieloma
Multiplo, Department of
Oncology, AOU Città della
Salute e della Scienza di Torino,
University of Torino, Torino,
Italy (S Bringhen MD PhD,
G Benevolo MD); Division of
Hematology, AOU Città della
Salute e della Scienza di Torino,
University of Torino and
Department of Molecular
Biotechnology and Health
Sciences, University of Torino,
Torino, Italy (L Cani MD,
A Larocca MD PhD,
Prof B Bruno MD PhD,
M D’Agostino MD);
UO Ematologia, AOU Careggi,
Firenze, Italy (E Antonioli MD);
SC di Ematologia e CTMO,
Ospedale Oncologico di
Riferimento Regionale
“A Businco”, ARNAS “G Brotzu”,
Cagliari, Italy (D Derudas MD);
Azienda Ospedaliero-
Universitaria Policlinico
Umberto I, Hematology,
Department of Translational
and Precision Medicine,
Sapienza University, Roma,
Italy (F Fazio MD PhD);
IRCCS Istituto Romagnolo
per lo Studio dei Tumori (IRST)
“Dino Amadori”, Meldola,
Italy (S Ronconi MD);
AUSL Romagna, Ospedale
Santa Maria delle Croci,
Ravenna, Italy
(C Cellini MD PhD); Hematology,
IRCCS “Casa Sollievo della
Sofferenza” Hospital,
San Giovanni Rotondo, Italy
(A P Falcone MD PhD); UOC di
Oncoematologia, Azienda
Ospedaliera Ospedali Riuniti
Villa Sofia Cervello, Palermo,
Italy (F Accardi MD PhD);
AO Santa Maria di Terni,
Università degli Studi di
Perugia, Perugia–Terni, Italy
(Prof A M Liberati MD);
UOC Ematologia e Terapia
cellulare, Ospedale C e
G Mazzoni, Ascoli Piceno, Italy
(P Galieni MD); Department of
Hematology, ASST Spedali
Civili di Brescia, Brescia, Italy
(A Belotti MD); SC Ematologia,
ASST GOM Niguarda, Milano,
Italy (A M Cafro MD); University
of Bari Aldo Moro Medical
School, Department of
Precision and Regenerative
Medicine and Ionian Area
(DiMePRe-J), Bari, Italy
(Prof R Ria MD); Hematology
Unit, Department of Hemato-
Oncology and Radiotherapy,
Grande Ospedale
Metropolitano “Bianchi-
Melacrino-Morelli”, Reggio
Calabria, Italy (I D Vincelli MD);
Oncology-Hematology
Department, Papardo Hospital,
Messina, Italy (D Mannina MD);
Sezione di Ematologia e
Immunologia Clinica, Ospedale
Santa Maria della Misericordia,
località Sant’Andrea delle
Fratte, Perugia, Italy
(F Lotti MD PhD); Hematology
Division, Fondazione
IRCCS Istituto Nazionale dei
Tumori di Milano, Milano, Italy
(V Marasco MD); Department of
Oncology and Hematology,
IRCCS Humanitas Research
Hospital, Rozzano, Milano,
Italy (R Mazza MD);
UO Ematologia, Ospedale di
Rimini, Rimini, Italy
(P Tosi MD); Azienda USL-IRCCS
di Reggio Emilia, Reggio Emilia,
Italy (E Rivolti MD); European
Myeloma Network, Italy
(Prof M Boccadoro MD)
Safety and Efficacy of Elranatamab in Patients with Relapsed and/or Refractory immunoglobulin Light-Chain Amyloidosis
Vianna P, et al.
Blood
July 2025
Authors and Affiliates
Pedro Vianna1,2,3, Rajshekar Chakraborty4, Shahrier Hossain2, Divaya Bhutani4, Shannon Miller2,
Annemarie Rossi2, Sarah A. M. Cuddy3,5, Rodney H. Falk3,5, Suzanne Lentzsch4, Jacob Laubach2,3,
Giada Bianchi1,2,3*
1Amyloidosis Program, Division of Hematology, Department of Medicine, Brigham and Women's
Hospital, Harvard Medical School, Boston, MA, 2Jerome Lipper Multiple Myeloma Center,
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. 3Harvard
Medical School, Boston, MA; 4Division of Hematology-Oncology, Columbia University Irving
Medical Center, New York, NY, 5Amyloidosis Program, Cardiovascular Division, Department of
Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
Belantamab mafodotin plus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): updated overall survival analysis from a global, randomised, open-label, phase 3 trial
Hungria V, et al.
Lancet Oncology
July 2025
Authors and Affiliates
Vania Hungria, Paweł Robak, Marek Hus, Vera Zherebtsova, Christopher Ward, P Joy Ho, Roman Hájek, Kihyun Kim, Sebastian Grosicki,
Hanlon Sia, Adam Bryant, Marcelo Pitombeira de Lacerda, Gracia Aparecida Martinez, Anna Sureda Balarí, Irwindeep Sandhu,
Claudio Cerchione, Peter Ganly, Meletios A Dimopoulos, Chengcheng Fu, Mamta Garg, Al-Ola Abdallah, Moshe E Gatt,
Albert Oriol Rocafiguera, Michele Cavo, Robert Rifkin, Tomoaki Fujisaki, Michał Mielnik, Joseph Ficek, Alejandro Mantero, Nick Pirooz,
Sybil Varghese, Joe Lee, Astrid McKeown, Rachel Rogers, Hena Baig, Lydia Eccersley, Sumita Roy-Ghanta, Pralay Mukhopadhyay,
Jacqueline Nielsen, Joanna Opalinska, María-Victoria Mateos, on behalf of the DREAMM-7 study investigators
Clinica São Germano, São
Paulo, Brazil (V Hungria MD);
Medical University of Łódź,
Łódź, Poland (Prof P Robak MD);
Samodzielny Publiczny Szpital
Kliniczny, Lublin, Poland
(Prof M Hus MD, M Mielnik MD);
Gorodskaya Klinicheskaya
Bol’nitsa Im Sp Botkina,
Moscow, Russia
(V Zherebtsova MD); Royal
North Shore Hospital, Sydney,
NSW, Australia
(Prof C Ward MD); Royal Prince
Alfred Hospital, Camperdown,
NSW, Australia
(Prof P J Ho MBBS); University
Hospital Ostrava and
University of Ostrava, Ostrava,
Czech Republic
(Prof R Hájek MD);
Sungkyunkwan University,
Samsung Medical Center,
Seoul, South Korea
(Prof K Kim MD); Medical
University of Silesia, Katowice,
Poland (Prof S Grosicki MD);
Pindara Private Hospital, Gold
Coast, QLD, Australia
(H Sia MBBS); Liverpool
Hospital, Sydney, NSW,
Australia (A Bryant PhD);
Universidade da Região de
Joinville and Centro de
Hematologia e Oncologia,
Joinville, Santa Catarina, Brazil
(Prof M Pitombeira de Lacerda
MD); Hospital das Clínicas and
Instituto do Câncer do Estado
de São Paulo, Universidade de
São Paulo, São Paulo, Brazil
(G A Martinez MD); Institut
Català d’Oncologia-
L’Hospitalet L.-Barcelona,
Barcelona, Spain
(A Sureda Balarí MD); Cross
Cancer Institute, Edmonton,
AB, Canada (I Sandhu MD);
Hematology Unit, Istituto
Romagnolo per lo Studio dei
Tumori “Dino Amadori” - IRST
IRCCS, Meldola, Forlì-Cesena,
Italy (C Cerchione MD);
Christchurch Hospital,
Christchurch, New Zealand
(P Ganly PhD); School of
Medicine, National and
Kapodistrian University of
Athens, Athens, Greece
(Prof M A Dimopoulos MD);
Korea University, Seoul,
South Korea
(Prof M A Dimopoulos); The
First Affiliated Hospital of
Soochow University, Jiangsu,
China (Prof C Fu MD); University
Hospitals of Leicester NHS
Trust, Leicester, UK
(M Garg MD); University of
Kansas Cancer Center, Fairway,
KS, USA (A-O Abdallah MD);
Department of Haematology,
Hadassah Medical Center,
Faculty of Medicine, Hebrew
University of Jerusalem,
Jerusalem, Israel (M E Gatt MD);
Institut Català d’Oncologia and
Josep Carreras Research
Institute, Hospital Germans
Trias i Pujol, Badalona, Spain
(A Oriol Rocafiguera MD);
Department of Medical and
Surgical Sciences, University of
Bologna, Bologna, Italy
(Prof M Cavo MD); Rocky
Mountain Cancer Centers—
Denver—Midtown, Denver, CO,
USA (R Rifkin MD); Matsuyama
Red Cross Hospital,
Matsuyama, Japan
(T Fujisaki MD); GSK,
Collegeville, PA, USA
(J Ficek PhD, A Mantero PhD,
N Pirooz MHA, S Varghese MBBS,
R Rogers MS, S Roy-Ghanta MD,
P Mukhopadhyay PhD,
J Opalinska MD); GSK, London,
UK (J Lee PhD, L Eccersley PhD);
GSK, Stevenage, UK
(A McKeown PhD); GSK,
Mississauga, ON, Canada
(H Baig BS); GSK, Chicago, IL,
USA (J Nielsen PhD); Instituto
de Investigación Biomédica de
Salamanca, Hospital
Universitario de Salamanca–
IBSAL–CIC–Ciberonc,
Salamanca, Spain
(M-V Mateos MD)
Subcutaneous epcoritamab monotherapy in Japanese patients with relapsed or refractory follicular lymphoma: primary results of the EPCORE NHL-3 trial
Izutsu K, et al.
Leukemia Lymphoma
July 2025
Authors and Affiliates
Koji Izutsua, Daigo Akahaneb, Tomomi Toubaic, Toko Saitod, Yuko Mishimae, Tomoaki Fujisakif,
Momoko Nishikorig, Takahiro Kumodeh, Youko Suehiroi, Kenji Ishitsukaj, Rebekah Conlonk,
Ami Takahashil, Barbara D’Angelo Månssonm, Elena Favarom and Noriko Fukuharan
aDepartment of Hematology, National Cancer Center Hospital, Tokyo, Japan; bDepartment of Hematology, Tokyo Medical University,
Tokyo, Japan; cDepartment of Internal Medicine III, Division of Hematology and Cell Therapy, Yamagata University Faculty of Medicine,
Yamagata, Japan; dDepartment of Hematology and Cell Therapy, Aichi Cancer Center Hospital, Nagoya, Japan; eDepartment of
Hematology Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan; fDepartment of Hematology,
Japan Red Cross Society, Matsuyama Red Cross Hospital, Matsuyama, Japan; gDepartment of Hematology, Graduate School of Medicine,
Kyoto University, Kyoto, Japan; hDepartment of Hematology and Rheumatology, Kindai University, Osaka, Japan; iDepartment of
Hematology and Cell Therapy, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan; jDepartment of Hematology and
Rheumatology, Kagoshima University, Kagoshima, Japan; kAbbVie, North Chicago, IL, USA; lGenmab, Tokyo, Japan; mGenmab,
Copenhagen, Denmark; nDepartment of Hematology, Tohoku University, Sendai, Japan
Venetoclax or placebo in combination with bortezomib and dexamethasone in relapsed or refractory multiple myeloma (BELLINI): final overall survival results from a randomised, phase 3 study
Kumar S, et al.
Lancet Haematology
June 2025
Authors and Affiliates
Shaji K Kumar, Simon J Harrison, Michele Cavo, Javier de la Rubia, Rakesh Popat, Cristina Gasparetto, Vania Hungria, Hans Salwender,
Kenshi Suzuki, Inho Kim, Maika Onishi, Grace Ku, Rajvineeth Pothacamury, Muhammad Jalaluddin, Jiewei Zeng, Jeremy A Ross,
Edyta Dobkowska, Philippe Moreau
Mayo Clinic, Rochester, MN,
USA (Prof S K Kumar MD);
Peter MacCallum Cancer Centre
and Royal Melbourne Hospital,
Melbourne, VIC, Australia
(Prof S J Harrison PhD);
Sir Peter MacCallum
Department of Oncology,
University of Melbourne,
Parkville, VIC, Australia
(Prof S J Harrison);
IRCCS Azienda Ospedaliero-
Universitaria di Bologna,
Seragnoli Institute
of Hematology, Bologna
University School of Medicine,
Bologna, Italy
(Prof M Cavo MD); Hematology
Service Hospital La Fe, IIS La Fe,
and School of Medicine and
Dentistry, Catholic University
of Valencia, Valencia, Spain
(Prof J de la Rubia MD);
University College London
Hospitals
NHS Foundation Trust,
London, UK (R Popat FRCPath);
Duke University Medical
Center, Durham, NC, USA
(Prof C Gasparetto MD); Clinica
São Germano, São Paulo, Brazil
(Prof V Hungria MD); Asklepios
Tumorzentrum Hamburg,
AK Altona and AK St Georg,
Hamburg, Germany
(H Salwender MD); Japanese
Red Cross Medical Center,
Tokyo, Japan
(Prof K Suzuki MD); Seoul
National University, Seoul,
South Korea (Prof I Kim MD);
Genentech, Inc, South
San Francisco, CA, USA
(M Onishi MD, G Ku MD);
AbbVie, North Chicago, IL,
USA (R Pothacamury MD,
M Jalaluddin PhD, J Zeng PhD,
J A Ross PhD); AbbVie,
Schaffhausen, Switzerland
(E Dobkowska MD); University
Hospital Hôtel-Dieu, Nantes,
France (Prof P Moreau MD)
Measurable Residual Disease-Guided Therapy in Newly Diagnosed Myeloma
Perrot A, et al.
June 2025
Authors and Affiliates
Aurore Perrot, M.D.,1 Jérôme Lambert, Ph.D.,2 Cyrille Hulin,
M.D.,3 Andrea Pieragostini, M.D.,4 Lionel Karlin, M.D.,5 Bertrand
Arnulf, M.D.,6 Philippe Rey, M.D.,7 Laurent Garderet,
M.D.,8 Margaret Macro, M.D.,9 Martine Escoffre‑Barbe, M.D.,10
Julie Gay, M.D.,11 Thomas Chalopin, M.D.,12 Romain Gounot,
M.D.,13 Jean‑Marc Schiano, M.D.,14 Mohamad Mohty, M.D.,15
Xavier Leleu, M.D.,16 Salomon Manier, M.D.,17 Clara Mariette,
M.D.,18 Carine Chaleteix, M.D.,19 Thorsten Braun, M.D.,20 Bernard
De Prijck, M.D.,21 Hervé Avet‑Loiseau, M.D.,22 Jean‑Yves
Mary, Ph.D.,2 Jill Corre, Pharm.D.,22 Philippe Moreau, M.D.,23
and Cyrille Touzeau, M.D.23
1 Service Hématologie, Hôpital Universitaire de Toulouse Oncopole,
Université de Toulouse, Toulouse, France; 2 Biostatistics
and Medical Information Department, Hôpital St. Louis,
Paris; 3 Service d’Hématologie, Hôpital Haut Lévêque, Centre
Hospitalier Universitaire (CHU) de Bordeaux, Pessac, France;
4 Service Hématologie, Hôpital Universitaire de Dijon, Dijon,
France; 5 Service Hématologie, Hôpital Universitaire Lyon Sud,
Pierre-Bénite, France; 6 Hôpital Universitaire St. Louis, Assistance
Publique–Hôpitaux de Paris (AP-HP), Paris; 7 Centre
Léon Bérard, Lyon, France; 8 Service Hématologie, Hôpital Universitaire
Pitié-Salpêtrière, AP-HP, Paris; 9 Service Hématologie,
Institut Hématologie de Basse Normandie, Hôpital Universitaire
de Caen, Caen, France; 10 Service Hématologie, Hôpital
Universitaire de Rennes, Rennes, France; 11 Hôpital de Bayonne,
Bayonne, France; 12 Service Hématologie, Hôpital Universitaire
de Tours, Tours, France; 13 Service Hématologie, Hôpital Henri
Mondor, Créteil, France; 14 Service Hématologie, Institut Paoli-
Calmettes, Marseille, France; 15 Service Hématologie, Hôpital
Universitaire St. Antoine, AP-HP, Université Sorbonne, Paris;
16 Service Hématologie, Hôpital Universitaire de Poitiers,
Poitiers, France; 17 Service Hématologie, Hôpital Universitaire
de Lille, Lille, France; 18 Service Hématologie, Hôpital CHU de
Grenoble, Grenoble, France; 19 Service Hématologie, Hôpital
Universitaire de Clermont-Ferrand, Clermont-Ferrand, France;
20 Service Hématologie, Hôpital Avicenne, AP-HP, Paris; 21 Service
Hématologie, Hôpital Universitaire de Liège, Liège, Belgium;
22 Unité Génomique du Myélome, Hôpital Universitaire
de Toulouse Oncopole, Université de Toulouse, Toulouse,
France; 23 Service Hématologie, Hôpital Universitaire
Minimal residual disease measurement in blood by mass spectrometry identifies long-term responders in multiple myeloma
Kubicki T, et al.
Blood Neoplasia
June 2025
Authors and Affiliates
Tadeusz Kubicki,1,2 Benjamin A Derman,1 Jennifer H Cooperrider,1 Anna
Puła,1,3 David Barnidge,4 Dominik Dytfeld,2 Ken Jiang,1 Andrzej J Jakubowiak1
1University of Chicago, Chicago, Illinois, USA; 2Poznan University of
Medical Sciences, Poznan, Poland; 3 Medical University of Lodz, Lodz, Poland 4Binding
Site, part of Thermo Fisher, Rochester, NY, USA
Long-Term (≥5-Year) Remission and Survival After Treatment With Ciltacabtagene Autoleucel in CARTITUDE-1 Patients With Relapsed/Refractory Multiple Myeloma
Jagannath S, et al
J Clin Oncol
June 2025
Authors and Affiliates
Sundar Jagannath, MD, FASCO1 ; Thomas G. Martin, MD2; Yi Lin, MD, PhD3 ; Adam D. Cohen, MD4 ; Noopur Raje, MD5 ; Myo Htut, MD6;
Abhinav Deol, MD7 ; Mounzer Agha, MD8 ; Jesus G. Berdeja, MD9 ; Alexander M. Lesokhin, MD10; Jessica J. Liegel, MD11 ;
Adriana Rossi, MD1 ; Alex Lieberman-Cribbin, MPH, CCRP1 ; Saad Z. Usmani, MD, MBA, FACP, FASCO10 ; Binod Dhakal, MD12 ;
Samir Parekh, MD1 ; Hui Li, PhD13; Feng Wang, PhD13; Rocio Montes de Oca, PhD14 ; Vicki Plaks, PhD, LLB14; Huabin Sun, MD15;
Arnob Banerjee, MD, PhD14; Jordan M. Schecter, MD15; Nikoletta Lendvai, MD, PhD15; Deepu Madduri, MD15; Tamar Lengil, PhD15; Jieqing Zhu, PhD16;
Mythili Koneru, MD, PhD16; Muhammad Akram, MD16; Nitin Patel, BM BCh16; Octavio Costa Filho, MD16; Andrzej J. Jakubowiak, MD, PhD17 ; and
Peter M. Voorhees, MD18
1Icahn School of Medicine at Mount Sinai, New York, NY
2University of California, San Francisco, San Francisco, CA
3Mayo Clinic, Rochester, MN
4Abramson Cancer Center, Perelman School of Medicine, University of
Pennsylvania, Philadelphia, PA
5Massachusetts General Hospital Cancer Center, Boston, MA
6Department of Hematology and Hematopoietic Cell Transplantation,
City of Hope Comprehensive Cancer Center, Duarte, CA
7Karmanos Cancer Institute, Wayne State University, Detroit, MI
8UPMC Hillman Cancer Center, Pittsburgh, PA
9Tennessee Oncology, Nashville, TN
10Memorial Sloan Kettering Cancer Center, New York, NY
11Division of Hematologic Malignancies and Bone Marrow
Transplantation, Department of Medicine, Beth Israel Deaconess
Medical Center, Boston, MA
12Medical College of Wisconsin, Milwaukee, WI
13Johnson & Johnson, Shanghai, China
14Johnson & Johnson, Spring House, PA
15Johnson & Johnson, Raritan, NJ
16Legend Biotech USA Inc, Somerset, NJ
17University of Chicago, Chicago, IL
18Atrium Health/Levine Cancer Institute, Wake Forest University School
of Medicine, Charlotte, NC
Previous
Next